Henan Taloph Pharmaceutical StockLtd Valuation

Is 600222 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600222 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 600222's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 600222's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600222?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 600222. This is calculated by dividing 600222's market cap by their current preferred multiple.
What is 600222's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥2.95b

600222 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.8x
Enterprise Value/EBITDA	25.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 600222's PE Ratio compare to its peers?

The above table shows the PE ratio for 600222 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	39.1x
600513 Jiangsu Lianhuan Pharmaceutical	20.6x	n/a	CN¥2.8b
300452 Anhui Sunhere Pharmaceutical ExcipientsLtd	19.5x	18.0%	CN¥3.2b
000153 Anhui Fengyuan Pharmaceutical	18.6x	n/a	CN¥3.0b
300583 Shandong Sito Bio-technology	97.6x	28.9%	CN¥3.3b
600222 Henan Taloph Pharmaceutical StockLtd	48.2x	n/a	CN¥2.9b

Price-To-Earnings vs Peers: 600222 is expensive based on its Price-To-Earnings Ratio (48.2x) compared to the peer average (39.1x).

Price to Earnings Ratio vs Industry

How does 600222's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 600222 is expensive based on its Price-To-Earnings Ratio (48.2x) compared to the CN Pharmaceuticals industry average (32.4x).

Price to Earnings Ratio vs Fair Ratio

What is 600222's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600222 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	48.2x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600222's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.